#PRESS Oral product 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial Novo Nordisk (@novonordisk) May 22, 2023 A release date for the pill has yet to be made public because the company still needs to submit the results to regulating authorities to obtain approval
Not having documentation may result in a less than favorable outcome
Semaglutide, the active ingredient in Ozempic and Wegovy, is a GLP-1 receptor agonist that acts on appetite signaling and the rate at which the stomach empties
Semaglutide has been shown to reduce the risk of major cardiovascular events like stroke and heart attack in people with type 2 diabetes and established cardiovascular disease
however, semaglutide is usually well tolerated
While its convenient for receiving non-controlled prescriptions, the lack of provider oversightat least on a face-to-face levelleads us to recommend this service only for people who need refills on an existing prescription